Efficacy and tolerability of brodimoprim at two different dosage schedules in the treatment of acute uncomplicated bacterial cystitis: Comparative study vs. pefloxacin

E. V. Cosmi, L. Cantini, P. A. Monici Preti, G. C. Di Renzo, F. Abate, G. Balsotti, G. Carlomagno, E. Cirese, R. Indraccolo, G. B. La Sala, L. Mearini, M. Minozzi, F. Scarpello

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In an open study, 172 male and female adult patients with acute uncomplicated bacterial cystitis were randomly allocated to three treatment groups. Two groups received brodimoprim 200 mg tablets as follows: a single dose of two 200 mg tablets on day 1, followed by one tablet per day on days 2 and 3 (58 patients); or a single daily dose of two tablets, for 2 days (63 patients). The third group received a single dose of pefloxacin, as two 400 mg tablets, for I day (51 patients). Complete urinalysis, sediment and urine culture examinations were carried out before treatment and 10 days after the last dose. Evaluation also comprised, at the time of enrolment and 48 h after the last dose, measurement of corporal temperature and assessment of symptoms (dysuria, pollakiuria, strangury, suprapubic pain, burning sensation during urination and urgency) on a 4-point scale. The eradication rate for the pathogen concerned was 98.3% and 96.7% in the groups receiving brodimoprim for 3 and 2 days, respectively, and 92.8% in the pefloxacin group (between-group comparison n.s.). There was significant regression of symptoms (P <0.001) in the three groups (between-groups comparison n.s.). Mainly gastrointestinal adverse events occurred in 3 patients receiving brodimoprim for 2 days and in 4 patients from each of the other two groups.

Original languageEnglish
Pages (from-to)207-211
Number of pages5
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume64
Issue number2
DOIs
Publication statusPublished - Feb 1996

Fingerprint

Pefloxacin
Cystitis
Appointments and Schedules
Tablets
Therapeutics
Dysuria
Urinalysis
Symptom Assessment
Urination
brodimoprim
Urine
Pain
Temperature

Keywords

  • Acute bacterial cystitis
  • Brodimoprim
  • Pefloxacin

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Efficacy and tolerability of brodimoprim at two different dosage schedules in the treatment of acute uncomplicated bacterial cystitis : Comparative study vs. pefloxacin. / Cosmi, E. V.; Cantini, L.; Monici Preti, P. A.; Di Renzo, G. C.; Abate, F.; Balsotti, G.; Carlomagno, G.; Cirese, E.; Indraccolo, R.; La Sala, G. B.; Mearini, L.; Minozzi, M.; Scarpello, F.

In: European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 64, No. 2, 02.1996, p. 207-211.

Research output: Contribution to journalArticle

Cosmi, EV, Cantini, L, Monici Preti, PA, Di Renzo, GC, Abate, F, Balsotti, G, Carlomagno, G, Cirese, E, Indraccolo, R, La Sala, GB, Mearini, L, Minozzi, M & Scarpello, F 1996, 'Efficacy and tolerability of brodimoprim at two different dosage schedules in the treatment of acute uncomplicated bacterial cystitis: Comparative study vs. pefloxacin', European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 64, no. 2, pp. 207-211. https://doi.org/10.1016/0301-2115(95)02292-9
Cosmi, E. V. ; Cantini, L. ; Monici Preti, P. A. ; Di Renzo, G. C. ; Abate, F. ; Balsotti, G. ; Carlomagno, G. ; Cirese, E. ; Indraccolo, R. ; La Sala, G. B. ; Mearini, L. ; Minozzi, M. ; Scarpello, F. / Efficacy and tolerability of brodimoprim at two different dosage schedules in the treatment of acute uncomplicated bacterial cystitis : Comparative study vs. pefloxacin. In: European Journal of Obstetrics and Gynecology and Reproductive Biology. 1996 ; Vol. 64, No. 2. pp. 207-211.
@article{a3933ca761d04f56aad727afc601f8bb,
title = "Efficacy and tolerability of brodimoprim at two different dosage schedules in the treatment of acute uncomplicated bacterial cystitis: Comparative study vs. pefloxacin",
abstract = "In an open study, 172 male and female adult patients with acute uncomplicated bacterial cystitis were randomly allocated to three treatment groups. Two groups received brodimoprim 200 mg tablets as follows: a single dose of two 200 mg tablets on day 1, followed by one tablet per day on days 2 and 3 (58 patients); or a single daily dose of two tablets, for 2 days (63 patients). The third group received a single dose of pefloxacin, as two 400 mg tablets, for I day (51 patients). Complete urinalysis, sediment and urine culture examinations were carried out before treatment and 10 days after the last dose. Evaluation also comprised, at the time of enrolment and 48 h after the last dose, measurement of corporal temperature and assessment of symptoms (dysuria, pollakiuria, strangury, suprapubic pain, burning sensation during urination and urgency) on a 4-point scale. The eradication rate for the pathogen concerned was 98.3{\%} and 96.7{\%} in the groups receiving brodimoprim for 3 and 2 days, respectively, and 92.8{\%} in the pefloxacin group (between-group comparison n.s.). There was significant regression of symptoms (P <0.001) in the three groups (between-groups comparison n.s.). Mainly gastrointestinal adverse events occurred in 3 patients receiving brodimoprim for 2 days and in 4 patients from each of the other two groups.",
keywords = "Acute bacterial cystitis, Brodimoprim, Pefloxacin",
author = "Cosmi, {E. V.} and L. Cantini and {Monici Preti}, {P. A.} and {Di Renzo}, {G. C.} and F. Abate and G. Balsotti and G. Carlomagno and E. Cirese and R. Indraccolo and {La Sala}, {G. B.} and L. Mearini and M. Minozzi and F. Scarpello",
year = "1996",
month = "2",
doi = "10.1016/0301-2115(95)02292-9",
language = "English",
volume = "64",
pages = "207--211",
journal = "European Journal of Obstetrics, Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Efficacy and tolerability of brodimoprim at two different dosage schedules in the treatment of acute uncomplicated bacterial cystitis

T2 - Comparative study vs. pefloxacin

AU - Cosmi, E. V.

AU - Cantini, L.

AU - Monici Preti, P. A.

AU - Di Renzo, G. C.

AU - Abate, F.

AU - Balsotti, G.

AU - Carlomagno, G.

AU - Cirese, E.

AU - Indraccolo, R.

AU - La Sala, G. B.

AU - Mearini, L.

AU - Minozzi, M.

AU - Scarpello, F.

PY - 1996/2

Y1 - 1996/2

N2 - In an open study, 172 male and female adult patients with acute uncomplicated bacterial cystitis were randomly allocated to three treatment groups. Two groups received brodimoprim 200 mg tablets as follows: a single dose of two 200 mg tablets on day 1, followed by one tablet per day on days 2 and 3 (58 patients); or a single daily dose of two tablets, for 2 days (63 patients). The third group received a single dose of pefloxacin, as two 400 mg tablets, for I day (51 patients). Complete urinalysis, sediment and urine culture examinations were carried out before treatment and 10 days after the last dose. Evaluation also comprised, at the time of enrolment and 48 h after the last dose, measurement of corporal temperature and assessment of symptoms (dysuria, pollakiuria, strangury, suprapubic pain, burning sensation during urination and urgency) on a 4-point scale. The eradication rate for the pathogen concerned was 98.3% and 96.7% in the groups receiving brodimoprim for 3 and 2 days, respectively, and 92.8% in the pefloxacin group (between-group comparison n.s.). There was significant regression of symptoms (P <0.001) in the three groups (between-groups comparison n.s.). Mainly gastrointestinal adverse events occurred in 3 patients receiving brodimoprim for 2 days and in 4 patients from each of the other two groups.

AB - In an open study, 172 male and female adult patients with acute uncomplicated bacterial cystitis were randomly allocated to three treatment groups. Two groups received brodimoprim 200 mg tablets as follows: a single dose of two 200 mg tablets on day 1, followed by one tablet per day on days 2 and 3 (58 patients); or a single daily dose of two tablets, for 2 days (63 patients). The third group received a single dose of pefloxacin, as two 400 mg tablets, for I day (51 patients). Complete urinalysis, sediment and urine culture examinations were carried out before treatment and 10 days after the last dose. Evaluation also comprised, at the time of enrolment and 48 h after the last dose, measurement of corporal temperature and assessment of symptoms (dysuria, pollakiuria, strangury, suprapubic pain, burning sensation during urination and urgency) on a 4-point scale. The eradication rate for the pathogen concerned was 98.3% and 96.7% in the groups receiving brodimoprim for 3 and 2 days, respectively, and 92.8% in the pefloxacin group (between-group comparison n.s.). There was significant regression of symptoms (P <0.001) in the three groups (between-groups comparison n.s.). Mainly gastrointestinal adverse events occurred in 3 patients receiving brodimoprim for 2 days and in 4 patients from each of the other two groups.

KW - Acute bacterial cystitis

KW - Brodimoprim

KW - Pefloxacin

UR - http://www.scopus.com/inward/record.url?scp=9044240034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044240034&partnerID=8YFLogxK

U2 - 10.1016/0301-2115(95)02292-9

DO - 10.1016/0301-2115(95)02292-9

M3 - Article

C2 - 8820004

AN - SCOPUS:9044240034

VL - 64

SP - 207

EP - 211

JO - European Journal of Obstetrics, Gynecology and Reproductive Biology

JF - European Journal of Obstetrics, Gynecology and Reproductive Biology

SN - 0028-2243

IS - 2

ER -